Gynosant

Gynosant is a prescription oral medication whose active ingredient is fluconazole, an azole antifungal. Marketed in the European Union, it is supplied as an oral dosage form; the exact strength is not specified in the public data. Fluconazole inhibits fungal cytochrome P450 enzymes, blocking ergosterol synthesis and disrupting cell membranes. It is listed under ATC code J02AX02 and is used to treat several types of candidiasis.

Gynosant (fluconazole) is indicated for the treatment of fungal infections caused by susceptible Candida species and certain other fungi. It is commonly prescribed for infections of the genital, oral, esophageal, systemic, and central nervous system regions.

- Vulvovaginal candidiasis (yeast infection of the vagina and vulva) - Oropharyngeal and esophageal candidiasis (thrush affecting mouth and esophagus) - Systemic candidiasis (bloodstream or organ infection) - Cryptococcal meningitis (fungal infection of the brain membranes) - Prophylaxis of candidiasis in immunocompromised patients

Side effects of Gynosant vary in frequency and severity. Common reactions are usually mild and reversible, while serious events are rare but require immediate medical attention.

Common: - Nausea or vomiting - Abdominal discomfort or pain - Headache - Skin rash or pruritus - Diarrhea - Elevated liver enzymes (transaminases)

Serious: - Severe liver injury or hepatitis - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Anaphylaxis or severe allergic reaction - Blood dyscrasias such as neutropenia or thrombocytopenia

Before starting Gynosant, certain health considerations should be reviewed to minimize risk.

- Assess liver function; avoid use in patients with severe hepatic impairment. - Use caution in patients with renal dysfunction; dose adjustment may be required. - Review pregnancy and breastfeeding status; discuss potential risks with a healthcare professional. - Monitor for drug interactions, especially with medications metabolized by CYP450 enzymes. - Advise patients to report signs of severe skin reactions or liver problems promptly. - Consider baseline and periodic blood counts in patients receiving long‑term therapy.

Fluconazole can affect the metabolism of many drugs; some combinations should be avoided, while others require careful monitoring.

Avoid: - Cisapride, pimozide, and certain antiarrhythmics (risk of QT prolongation) - Rifampin or other strong CYP3A4 inducers (reduced fluconazole efficacy) - Certain statins (e.g., simvastatin, lovastatin) due to increased risk of myopathy - Oral anticoagulants such as warfarin (enhanced anticoagulant effect)

Use with caution: - Phenytoin, carbamazepine, or phenobarbital (possible dose adjustments) - Cyclosporine or tacrolimus (monitor blood levels for toxicity) - Oral hypoglycemics (potential for increased hypoglycemia) - Benzodiazepines metabolized by CYP3A4 (possible increased sedation)